Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFα therapy

Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFα therapy

Hubert Marotte, Pierre MiossecClinical Immunology Unit, Departments of Immunology and Rheumatology, University of Lyon, and Unité Mixte Hospices Civils de Lyon–bioMérieux, Hôpital Edouard Herriot, Lyon, FranceAbstract: This review focuses on...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hubert Marotte, Pierre Miossec
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/f894966d3ecc46ec8226c9d102eb9061
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f894966d3ecc46ec8226c9d102eb9061
record_format dspace
spelling oai:doaj.org-article:f894966d3ecc46ec8226c9d102eb90612021-12-02T04:42:40ZPrevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFα therapy1177-54751177-5491https://doaj.org/article/f894966d3ecc46ec8226c9d102eb90612008-08-01T00:00:00Zhttp://www.dovepress.com/prevention-of-bone-mineral-density-loss-in-patients-with-rheumatoid-ar-a2035https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Hubert Marotte, Pierre MiossecClinical Immunology Unit, Departments of Immunology and Rheumatology, University of Lyon, and Unité Mixte Hospices Civils de Lyon–bioMérieux, Hôpital Edouard Herriot, Lyon, FranceAbstract: This review focuses on recent advances in the effect of anti-TNFα therapy on bone metabolism and bone mineral density (BMD) in rheumatoid arthritis (RA). RA is a chronic disease characterized by inflammation of the synovial joint, cartilage degradation, and subsequent bone destruction. Bone damage is often manifested as erosions, localized juxta-articular bone loss, or generalized bone loss. Thus, blockade of TNFa not only serves to block inflammation, but also halts the erosive nature of RA and generalized/localized juxta-articular bone loss. Here, we review recent findings showing that anti-TNFa therapy is also effective on halting systemic bone loss. In vitro, TNFa reduces osteoblast activity and increases osteoclast activity through RANKL-RANK pathway. In arthritis animal models, an imbalance between bone formation and resorption is observed. In humans, this coupling of destruction is restored by anti-TNFα therapy early on, but only for a few months. Thus, anti-TNFα prevents the BMD loss in RA patients. In summary, TNFa blockade is not only able to prevent joint destruction, but it is also able to prevent bone loss in RA patients. Future studies are needed to address if TNFa blockers have an effect on bone fractures.Keywords: rheumatoid arthritis, TNFα, bone mineral density, infliximab Hubert MarottePierre MiossecDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 4, Pp 663-669 (2008)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Hubert Marotte
Pierre Miossec
Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFα therapy
description Hubert Marotte, Pierre MiossecClinical Immunology Unit, Departments of Immunology and Rheumatology, University of Lyon, and Unité Mixte Hospices Civils de Lyon–bioMérieux, Hôpital Edouard Herriot, Lyon, FranceAbstract: This review focuses on recent advances in the effect of anti-TNFα therapy on bone metabolism and bone mineral density (BMD) in rheumatoid arthritis (RA). RA is a chronic disease characterized by inflammation of the synovial joint, cartilage degradation, and subsequent bone destruction. Bone damage is often manifested as erosions, localized juxta-articular bone loss, or generalized bone loss. Thus, blockade of TNFa not only serves to block inflammation, but also halts the erosive nature of RA and generalized/localized juxta-articular bone loss. Here, we review recent findings showing that anti-TNFa therapy is also effective on halting systemic bone loss. In vitro, TNFa reduces osteoblast activity and increases osteoclast activity through RANKL-RANK pathway. In arthritis animal models, an imbalance between bone formation and resorption is observed. In humans, this coupling of destruction is restored by anti-TNFα therapy early on, but only for a few months. Thus, anti-TNFα prevents the BMD loss in RA patients. In summary, TNFa blockade is not only able to prevent joint destruction, but it is also able to prevent bone loss in RA patients. Future studies are needed to address if TNFa blockers have an effect on bone fractures.Keywords: rheumatoid arthritis, TNFα, bone mineral density, infliximab
format article
author Hubert Marotte
Pierre Miossec
author_facet Hubert Marotte
Pierre Miossec
author_sort Hubert Marotte
title Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFα therapy
title_short Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFα therapy
title_full Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFα therapy
title_fullStr Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFα therapy
title_full_unstemmed Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFα therapy
title_sort prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-tnfα therapy
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/f894966d3ecc46ec8226c9d102eb9061
work_keys_str_mv AT hubertmarotte preventionofbonemineraldensitylossinpatientswithrheumatoidarthritistreatedwithantitnfampalphatherapy
AT pierremiossec preventionofbonemineraldensitylossinpatientswithrheumatoidarthritistreatedwithantitnfampalphatherapy
_version_ 1718401105853939712

Ejemplares similares